Lifeboat Foundation

It could be lighter, thinner, more flexible and tougher than steel.

Here’s Liz Parrish talking about driving down costs, replacing viral vectors, and having all kinds of trouble with the lid of a bottle.

Liz Parrish, founder or Bioviva company, which developing genetic therapy against aging. He first in world tested such genetic therapy on himself and resulting effect make her cells be like 20 years younger.

Continue reading “3/3 Liz Parrish and Avi Roy: Genetic and other innovative therapy against aging” »

Imagine a couple wanting to have a baby. They see the fertility specialist at a clinic, provide genetic material such as sperm or skin cells, and return sometime later. ‘The DNA of the resulting embryos will then be sequenced and carefully analyzed before decisions are made about which embryo or embryos to transfer to a womb for possible development,’ Greely writes. ‘Prospective parents will be told as much as they wish to know about the genetic makeup of dozens of embryos, and they will pick one or two for implantation, gestation, and birth.’ Besides the advantages of eliminating certain diseases, ‘It will be safe, lawful, and free.’

Will we be building a better world or a more homogeneous one?

Continue reading “Someday those who engage in intercourse for reproduction purposes could become stigmatized” »

Scientists genetically engineered and 3D-printed a biohybrid being, opening the door further for lifelike robots and artificial intelligence.

By Lisa Calhoun

(NaturalNews) Earlier this month, Juno Therapeutics, a pioneer in the field of treating cancer using genetically engineered cells, had to halt the development of its lead treatment after the death of three leukemia patients enrolled in the study.

The Seattle-based biotech company reported that the deaths of all three patients, who were in their 20s, were linked to swelling in the brain. The swelling occurred after the company added a second chemotherapy drug to the treatment procedure.

The news of the patient deaths is a big blow for the biotech startup that is developing a new experimental therapy known as chimeric antigen receptor T-cell (or CART) immunotherapy. The setback will likely delay the company’s aim of introducing it to the market by 2017, Juno executives said in a conference.

Continue reading “FDA study using genetically engineered cells to treat cancer kills three people” »

Personally; I have heard this several years ago from some medical researchers. Glad that more have concluded this tie.

Genetic mutations on several genes including BRCA2 have been associated with prostate cancer; while in a separate study, a BRCA1 mutation has been linked to a particular form of uterine cancer.

The first study, published in the New England Journal of Medicine, found that 12 percent of men with advanced prostate cancer had inherited mutations in genes involved in the repair of damaged DNA.

Professor Johann de Bono of the Institute of Cancer Research in London and the Royal Marsden NHS Foundation Trust, who led the study, said: ‘Our study has shown that a significant proportion of men with advanced prostate cancer are born with DNA repair mutations – and this could have important implications for patients.

Luv it.

Microsoft and genetics boffins predict genetics in the datacenter.

Biocomputing/ living circuit computing/ gene circuitry are the longer term future beyond Quantum. Here is another one of the many building blocks.

The tiny molecule responsible for transmitting the genetic data for every living thing on earth could be the answer to the IT industry’s quest for a more compact storage medium. In fact, researchers from Microsoft and the University of Washington recently succeeded in storing 200 MB of data on a few strands of DNA, occupying a small dot on a test tube many times smaller than the tip of a pencil.

The Internet in a Shoebox.

Continue reading “Microsoft Testing DNA’s Data Storage Ability With Record-Breaking Results” »

A newly published study details how engineers developed programmable RNA vaccines that work against Ebola, H1N1 influenza, and a common parasites in mice.

MIT engineers have developed a new type of easily customizable vaccine that can be manufactured in one week, allowing it to be rapidly deployed in response to disease outbreaks. So far, they have designed vaccines against Ebola, H1N1 influenza, and Toxoplasma gondii (a relative of the parasite that causes malaria), which were 100 percent effective in tests in mice.

The vaccine consists of strands of genetic material known as messenger RNA, which can be designed to code for any viral, bacterial, or parasitic protein. These molecules are then packaged into a molecule that delivers the RNA into cells, where it is translated into proteins that provoke an immune response from the host.

Continue reading “Engineers Design Programmable RNA Vaccines That Protext Against Ebola and H1N1 Influenza” »